FDA Green Lights Roche's Polivy in First-Line DLBCL

The FDA has approved Roche-subsidiary Genentech’s Polivy (polatuzumab vedotin-piiq), as part of a five-drug regimen, for the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL), the company announced Thursday.